Index RUT
P/E -
EPS (ttm) -6.84
Insider Own 13.66%
Shs Outstand 81.12M
Perf Week -3.86%
Market Cap 3.10B
Forward P/E -
EPS next Y -6.72
Insider Trans 3.89%
Shs Float 76.23M
Perf Month -12.64%
Income -517.18M
PEG -
EPS next Q -1.81
Inst Own 84.38%
Short Float 12.12%
Perf Quarter -29.15%
Sales 0.00M
P/S -
EPS this Y -31.49%
Inst Trans 334.24%
Short Ratio 5.98
Perf Half Y 9.31%
Book/sh 3.68
P/B 9.53
EPS next Y 10.76%
ROA -99.74%
Short Interest 9.24M
Perf Year 100.46%
Cash/sh 3.23
P/C 10.87
EPS next 5Y -
ROE -133.69%
52W Range 16.30 - 62.21
Perf YTD -17.99%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -157.42%
52W High -43.58%
Beta 4.31
Dividend TTM -
Quick Ratio 4.03
Sales past 5Y 0.00%
Gross Margin -
52W Low 115.34%
ATR (14) 3.33
Dividend Ex-Date -
Current Ratio 4.03
EPS Y/Y TTM 16.13%
Oper. Margin 0.00%
RSI (14) 40.09
Volatility 12.26% 8.12%
Employees 239
Debt/Eq 0.10
Sales Y/Y TTM -
Profit Margin -
Recom 1.09
Target Price 57.89
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q -112.85%
Payout -
Rel Volume 0.84
Prev Close 35.23
Sales Surprise -
EPS Surprise -42.07%
Sales Q/Q -
Earnings May 09 AMC
Avg Volume 1.54M
Price 35.10
SMA20 -7.70%
SMA50 -20.32%
SMA200 -5.47%
Trades
Volume 1,295,034
Change -0.37%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-16-24 Initiated
RBC Capital Mkts
Outperform
$62
Feb-06-24 Initiated
UBS
Buy
$59
Dec-22-23 Initiated
H.C. Wainwright
Buy
$50
Dec-08-23 Initiated
Robert W. Baird
Outperform
$58
Jan-24-23 Initiated
SVB Securities
Outperform
$24
Jan-04-23 Initiated
JP Morgan
Overweight
$23
Dec-02-22 Initiated
BTIG Research
Buy
$24
Oct-26-22 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$158 → $27
Oct-12-22 Initiated
Piper Sandler
Overweight
$23
Aug-19-22 Downgrade
Piper Sandler
Overweight → Neutral
$149
Aug-08-22 Downgrade
Wedbush
Outperform → Neutral
$148.50
May-11-22 Downgrade
SVB Leerink
Outperform → Mkt Perform
$150
Oct-19-21 Resumed
Morgan Stanley
Equal-Weight
$107 → $145
Aug-10-21 Downgrade
UBS
Buy → Neutral
$108 → $109
Aug-03-21 Reiterated
Canaccord Genuity
Buy
$101 → $150
Mar-11-21 Initiated
UBS
Buy
$108
Dec-15-20 Initiated
H.C. Wainwright
Buy
$121
Apr-17-20 Initiated
Cowen
Outperform
$45
Feb-10-20 Downgrade
Oppenheimer
Outperform → Perform
Feb-06-20 Initiated
Mizuho
Buy
Show Previous Ratings
May-29-24 07:30AM
07:15AM
May-15-24 11:00AM
May-14-24 09:35AM
May-13-24 09:35AM
11:54PM
Loading…
May-09-24 11:54PM
04:05PM
May-01-24 02:38PM
Apr-26-24 06:00AM
Apr-25-24 11:00AM
Apr-23-24 11:00AM
Apr-22-24 04:05PM
Apr-18-24 06:00AM
Apr-17-24 04:05PM
Apr-13-24 09:00AM
10:03PM
Loading…
Apr-03-24 10:03PM
Feb-29-24 04:05PM
Jan-25-24 05:31PM
Jan-22-24 07:00AM
(The Wall Street Journal) +9.24%
Jan-08-24 07:30AM
Jan-02-24 07:00AM
Dec-31-23 03:01AM
Dec-01-23 04:30PM
Nov-16-23 09:40AM
Nov-14-23 09:15PM
04:05PM
Nov-06-23 08:50AM
Oct-31-23 09:40AM
Oct-19-23 08:50AM
Oct-16-23 07:00AM
01:01PM
Loading…
Oct-06-23 01:01PM
Oct-05-23 04:05PM
Oct-03-23 08:50AM
Oct-02-23 11:56PM
04:36PM
Sep-29-23 10:00AM
10:00AM
Sep-28-23 07:53AM
Sep-27-23 04:09PM
(Investor's Business Daily) +33.31%
12:25PM
(Investor's Business Daily)
12:00PM
Sep-14-23 07:00AM
Sep-05-23 07:00AM
Aug-09-23 06:01AM
Jul-31-23 09:31AM
06:59AM
Jul-27-23 12:50PM
07:00AM
Jun-27-23 05:31AM
Jun-02-23 09:11AM
Jun-01-23 04:08PM
(Investor's Business Daily) +18.39%
01:01PM
(Investor's Business Daily)
11:29AM
May-31-23 07:00AM
May-25-23 05:00PM
May-24-23 01:30PM
May-12-23 04:30PM
May-05-23 10:43AM
Apr-17-23 07:00AM
Mar-30-23 09:40AM
Mar-25-23 09:22AM
Mar-23-23 04:05PM
11:09AM
Mar-22-23 07:30AM
Mar-14-23 07:30AM
Mar-13-23 11:39AM
Feb-23-23 08:36AM
Feb-21-23 07:30AM
Feb-10-23 02:55PM
Feb-02-23 12:52PM
(Investor's Business Daily)
Jan-06-23 07:58AM
07:30AM
Jan-05-23 09:40AM
Dec-23-22 06:21AM
Nov-29-22 09:35AM
Nov-28-22 09:55AM
Nov-21-22 09:33AM
Nov-09-22 08:35AM
07:00AM
Nov-08-22 11:52AM
Nov-06-22 11:48AM
07:00AM
Nov-01-22 10:01AM
Oct-25-22 08:21PM
04:30PM
Oct-20-22 10:30PM
Oct-18-22 04:12PM
Oct-07-22 03:24AM
Oct-06-22 10:54AM
Oct-05-22 04:45PM
Oct-04-22 12:29PM
07:30AM
Oct-03-22 01:01PM
Sep-30-22 04:09PM
(Investor's Business Daily) -6.80%
01:04PM
Sep-29-22 04:09PM
(Investor's Business Daily) -11.05%
12:24PM
08:39AM
08:00AM
Sep-23-22 09:36AM
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
CHILDS JOHN W Director May 30 '24 Buy 35.58 28,000 996,240 2,311,341 May 31 09:04 AM CHILDS JOHN W Director May 13 '24 Buy 35.17 28,500 1,002,470 2,283,341 May 14 07:30 AM Bailey Gregory Director May 13 '24 Buy 34.19 15,000 512,877 1,615,071 May 15 07:31 AM Bailey Gregory Director Apr 24 '24 Buy 39.18 25,503 999,169 1,600,071 Apr 25 07:32 AM CHILDS JOHN W Director Apr 22 '24 Buy 41.00 195,121 7,999,961 4,096,512 Apr 23 07:54 AM Coric Vlad Chief Executive Officer Apr 22 '24 Buy 41.00 121,951 4,999,991 1,788,417 Apr 23 07:54 AM Bailey Gregory Director Apr 22 '24 Buy 41.00 48,780 1,999,980 1,574,568 Apr 23 07:54 AM Antonijevic Irina Director Dec 29 '23 Option Exercise 0.00 11,000 0 13,535 Dec 29 06:25 PM Antonijevic Irina Director Dec 29 '23 Sale 41.79 11,000 459,662 2,535 Dec 29 06:25 PM CHILDS JOHN W Director Oct 05 '23 Buy 22.00 454,545 9,999,990 3,998,952 Oct 10 07:07 PM Coric Vlad Chief Executive Officer Oct 05 '23 Buy 22.00 340,908 7,499,976 833,120 Oct 10 07:17 AM Coric Vlad Chief Executive Officer Oct 05 '23 Buy 22.00 113,637 2,500,014 1,657,031 Oct 10 07:17 AM Buten Matthew Chief Financial Officer Oct 05 '23 Buy 22.00 22,727 499,994 189,380 Oct 06 07:38 AM Bailey Gregory Director Oct 04 '23 Buy 22.57 17,817 402,094 1,525,788 Oct 06 07:37 AM CHILDS JOHN W Director Aug 30 '23 Buy 18.44 50,000 922,180 1,975,118 Aug 31 08:56 AM CHILDS JOHN W Director Aug 04 '23 Buy 19.78 100,000 1,978,430 1,925,118 Aug 07 07:29 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite